The Contracts Every Pharma Company Needs (and How to Manage Them) (2026)

Which contracts does a pharma company actually need? A pharmaceutical company contracts across one of the most regulated supply chains there is: research and clinical trials, manufacturing and quality, intellectual property and licensing, and distribution to patients. Each stage has its own specialised agreement, and each sits on top of strict drug-safety and pricing rules. A gap in a quality agreement or an unclear licence is not just a commercial problem, it can be a compliance and patient-safety problem. The list is long but finite. Here is the practical set an Indian pharma company typically needs, grouped by stage. This article is general guidance, not legal advice. Drug regulation is detailed and changes often, so have a qualified professional review your templates. ## Research and clinical contracts - Clinical trial agreements. Between the sponsor, the site and the investigator, covering conduct, data, safety reporting, compensation for trial-related injury and publication rights.

• Contract research organisation (CRO) agreements. For outsourcing trial management, with responsibility, data and compliance terms.
• Material transfer agreements (MTAs). For sharing compounds, samples or biological materials, with use limits and IP terms.
• Informed consent documentation. Required for participants, under the clinical-trial rules. ## Manufacturing and quality contracts - Manufacturing or contract manufacturing (CMO) agreements. For making product, often with a loan-licence or principal-to-principal structure.
• Quality or technical agreements. The document that allocates good-manufacturing-practice responsibilities between the parties, central to regulatory compliance.
• API and raw-material supply agreements. For active ingredients and excipients, with specification, quality and continuity terms. ## Intellectual property and licensing contracts - Technology and patent licensing agreements. For in-licensing or out-licensing molecules, processes or know-how.
• Collaboration and co-development agreements. For joint research or development, with clear IP ownership and milestone terms.
• Confidentiality agreements for sharing sensitive data with partners.
• Trademark and brand-licensing agreements. For brand names and marks, which carry real value in pharma, with quality-control terms so licensed products meet your standards. ## Distribution and commercial contracts - Distribution and stockist agreements. For getting product to market through distributors and stockists.
• Carrying-and-forwarding (C&F) agent agreements. For warehousing and dispatch in a region.
• Supply agreements with hospitals and institutions. Often involving tenders and specific terms.
• Pharmacovigilance or safety data exchange agreements. For sharing adverse-event and safety data with partners and licensees, which regulators expect to be documented and kept current. ## People and corporate contracts - Employment and contractor agreements with confidentiality and IP assignment, important given sensitive research.
• Shareholders' and fundraising documents for the wider business. ## A note on regulation Pharma contracts sit on top of strict drug-safety, trial and pricing rules, and the detail changes often. In India, the manufacture, sale and quality of drugs engage the Drugs and Cosmetics Act, 1940, and the rules under it; clinical trials engage the New Drugs and Clinical Trials Rules, 2019, administered by the Central Drugs Standard Control Organisation (CDSCO), which set timelines, ethics-committee requirements and compensation duties; drug pricing engages the Drugs (Prices Control) Order, 2013, administered by the National Pharmaceutical Pricing Authority (NPPA); and patents engage the Patents Act, 1970. Patient and trial data engage the Digital Personal Data Protection Act, 2023. Because safety, trial and pricing rules are strict and change, treat your contracts as living documents and confirm current requirements. Last verified October 2026. ## How to keep all of this under control Having the templates is the easy part. The hard part is the ongoing work, where pharma teams face compliance and quality exposure. 1. Keep one source of truth. Store every signed agreement in one place, linked to the product, trial or site, so you can respond fast to an audit or a safety event.

2. Standardise your templates. One clinical trial agreement, one quality agreement, one distribution agreement, with deliberate exceptions, so safety and responsibility terms stay consistent.
3. Map contracts to regulation. Know which rule each agreement supports, so a regulatory change tells you which contracts and quality agreements to update.
4. Track key dates and obligations. Trial milestones, safety-reporting duties, quality reviews, renewals and pricing-compliance obligations live in the body of the contract and bind you long after signing.
5. Review incoming redlines consistently. When a CRO, CMO or distributor edits your template, spot the shifted liability, the weaker quality duty or the data clause they changed, every time. ## Doing this in one workspace Read back over that list and a pattern appears. Drafting a clinical trial agreement from a template, checking a CMO's redline for a weak quality clause, remembering a safety-reporting or renewal date, keeping versions straight across a product, tracking a pricing-compliance obligation: these are not many separate jobs, they are one job done many times across scattered tools. The point of an AI contract workspace is to make them one connected job instead. It can draft each agreement from a template that fits how a pharma company contracts, read the contract as linked clauses so it flags risk clause by clause, let you edit terms in plain English, and keep key dates and obligations on a live activity timeline. Adira is one tool that keeps pharma contracts in a single workspace. You do not need a platform to start; a clean set of templates and one shared, product-linked folder will carry a growing pharma company a long way, and a workspace just keeps the work together as your trials, partners and products multiply.